Polymyalgia rheumatica and giant cell arteritis: Management of two diseases of the elderly

Christian Dejaco, Christina Duftner, Bhaskar Dasgupta, Eric L. Matteson, Michael Schirmer

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) present with a broad spectrum of clinical manifestations and almost exclusively occur in the population aged over 50 years. After rheumatoid arthritis, PMR is the second most common autoimmune rheumatic disorder. Visual loss is the most feared complication in temporal arteritis, and extracranial arteries and/or aorta are more often involved in GCA than previously estimated. No specific laboratory parameter exists for diagnosis of PMR. Imaging techniques such as ultrasonography, MRI or 18F-fluorodeoxyglucose PET may be helpful in the diagnosis and evaluation of the extent of vascular involvement in these diseases. This article highlights upcoming new classification criteria for PMR, recent advances of diagnostic and therapeutic procedures as well as ongoing research on biomarkers and corticosteroid-sparing medications, which should improve management of PMR and GCA.

Original languageEnglish (US)
Pages (from-to)633-645
Number of pages13
JournalAging Health
Issue number4
StatePublished - Aug 2011


  • aortic aneurysm
  • corticosteroids
  • disease activity
  • disease-modifying antirheumatic drugs
  • giant cell arteritis
  • outcome research
  • polymyalgia rheumatica
  • vasculitis

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Polymyalgia rheumatica and giant cell arteritis: Management of two diseases of the elderly'. Together they form a unique fingerprint.

Cite this